

TABLE OF CONTENTS

Chapter 1	
INTRODUCTION.....	1
Chapter 2	
FUNDAMENTAL CONCEPT OF BIOAVAILABILITY	7
I. DEFINITION OF BIOAVAILABILITY	7
A. UNALTERED FORM.....	7
B. SYSTEMIC CIRCULATION	8
C. RELATIONSHIP BETWEEN EXTENT AND RATE OF BIOAVAILABILITY	8
D. EXTENT OF BIOAVAILABILITY.....	9
1. Absolute bioavailability.....	10
2. Relative bioavailability.....	11
II. BIOAVAILABILITY IN HEALTH RISK ASSESSMENT.....	12
A. BIOLOGICALLY EFFECTIVE DOSE.....	13
B. INTERNAL DOSE AND AVERAGE DAILY INTERNAL DOSE	13
C. EXTERNAL DOSE AND AVERAGE DAILY EXTERNAL DOSE	16
III. SUMMARY	17
Chapter 3	
MECHANISM OF ABSORPTION.....	19
I. RESPIRATORY SYSTEM.....	19
A. STRUCTURE AND FUNCTION.....	19
B. RATE-LIMITING PROCESSES FOR GASEOUS PHASE CONTAMINANTS.....	22
C. OTHER FACTORS INFLUENCING RESPIRATORY BIOAVAILABILITY FOR GASES AND VAPORS.....	24
D. RATE-LIMITING PROCESSES FOR PARTICULATE PHASE CONTAMINANTS.....	26
1. Deposition	28
2. Clearance	33
a. Water Insoluble Aerosols	33
b. Water Soluble Aerosols	34
3. Retention.....	34
E. OTHER FACTORS INFLUENCING RESPIRATORY BIOAVAILABILITY FOR AEROSOLS.....	35
II. GASTROINTESTINAL SYSTEM.....	36
A. STRUCTURE AND FUNCTION.....	36
B. RATE-LIMITING PROCESSES.....	38
C. OTHER FACTORS INFLUENCING ORAL BIOAVAILABILITY.....	41

III. SKIN.....	44
A. STRUCTURE AND FUNCTION.....	44
B. RATE-LIMITING PROCESSES.....	45
C. OTHER FACTORS INFLUENCING DERMAL BIOAVAILABILITY.....	47
IV. SUMMARY.....	49

Chapter 4

EXPERIMENTAL METHODS FOR EVALUATING BIOAVAILABILITY.....	51
I. GENERAL <i>IN VIVO</i> METHODS.....	51
A. MEASUREMENT OF BLOOD LEVELS.....	51
B. MEASUREMENT OF THE CUMULATIVE URINARY EXCRETION.....	53
C. MASS-BALANCE TECHNIQUE.....	54
D. MEASUREMENT OF TOXIC RESPONSE.....	56
II. SPECIFIC METHODS FOR THE INHALATION EXPOSURE ROUTE.....	56
A. DETERMINATION OF DEPOSITION FRACTION.....	57
1. Gaseous Phase.....	57
2. Particulate Phase.....	59
B. MECHANICAL CLEARANCE FRACTION.....	59
C. DISSOLUTION RATE.....	60
D. <i>IN VITRO</i> METHODS: ISOLATED PERFUSED LUNG.....	61
III. SPECIFIC METHODS FOR THE INGESTION EXPOSURE ROUTE.....	62
A. MEASUREMENT OF FECAL EXCRETION.....	64
B. MEASUREMENT OF LIVER RATIO.....	65
C. DISSOLUTION TESTING.....	65
D. METHODS BASED ON THE pH PARTITION THEORY.....	66
IV. SPECIFIC METHODS FOR DERMAL EXPOSURE ROUTE.....	66
A. SURFACE DISAPPEARANCE.....	67
B. <i>IN VITRO</i> METHODS: BIOLOGICAL MEMBRANE MODELS.....	67
C. <i>IN VITRO</i> METHODS: ARTIFICIAL MEMBRANE MODELS.....	69
V. SUMMARY.....	70

Chapter 5

EXPOSURE ROUTES AND BIOAVAILABILITY FACTORS FOR SELECTED CONTAMINANTS.....	75
I. ARSENIC.....	75

A.	EXPOSURE ROUTES AND RECEPTORS.....	76
B.	TOXICOKINETICS (FOLLOWING ABSORPTION).....	77
	1. Distribution.....	77
	2. Metabolism and Excretion.....	77
C.	BIOAVAILABILITY.....	78
	1. Inhalation.....	78
	a. Humans.....	78
	b. Animals.....	78
	2. Ingestion.....	80
	a. Humans.....	80
	b. Animals.....	81
	3. Dermal	82
	4. Summary.....	82
D.	UNCERTAINTIES	82
E.	CONCLUSIONS.....	89
F.	RECOMMENDATIONS.....	90
II.	CADMIUM.....	91
A.	EXPOSURE ROUTES AND RECEPTORS.....	91
B.	TOXICOKINETICS (FOLLOWING ABSORPTION).....	92
	1. Distribution.....	92
	2. Metabolism and Excretion.....	92
C.	BIOAVAILABILITY.....	92
	1. Inhalation.....	92
	2. Ingestion.....	94
	3. Dermal	95
	4. Summary.....	95
D.	UNCERTAINTIES	95
E.	CONCLUSIONS.....	100
F.	RECOMMENDATIONS.....	100
III.	CHROMIUM AND CHROMIUM COMPOUNDS.....	101
A.	EXPOSURE ROUTES AND RECEPTORS.....	102
B.	TOXICOKINETICS (FOLLOWING ABSORPTION).....	103
	1. Distribution.....	103
	2. Metabolism and Excretion.....	103
C.	BIOAVAILABILITY.....	103
	1. Inhalation.....	103
	a. Humans.....	103
	b. Animals.....	104
	2. Ingestion.....	105
	a. Humans.....	105
	b. Animals	106
	c. Others	106
	3. Dermal	106
	4. Summary.....	107
D.	UNCERTAINTIES	107

E. CONCLUSIONS.....	115
F. RECOMMENDATIONS.....	116
IV. COPPER.....	117
A. EXPOSURE ROUTES AND RECEPTORS.....	117
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	118
1. Distribution.....	118
2. Metabolism and Excretion.....	118
C. BIOAVAILABILITY.....	119
1. Inhalation.....	119
2. Ingestion.....	119
3. Dermal	120
D. UNCERTAINTIES	120
E. CONCLUSIONS.....	121
F. RECOMMENDATIONS.....	124
V. MERCURY.....	125
A. EXPOSURE ROUTES AND RECEPTORS.....	125
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	126
1. Distribution.....	126
2. Metabolism and Excretion.....	126
C. BIOAVAILABILITY.....	127
1. Inhalation.....	127
2. Ingestion.....	127
3. Dermal	128
4. Summary.....	128
D. UNCERTAINTIES	129
E. CONCLUSIONS.....	129
F. RECOMMENDATIONS.....	133
VI. LEAD.....	134
A. EXPOSURE ROUTES AND RECEPTORS.....	134
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	135
1. Distribution.....	135
2. Metabolism and Excretion.....	136
C. BIOAVAILABILITY.....	136
1. Inhalation.....	136
2. Ingestion.....	137
3. Dermal	138
4. Summary.....	139
D. UNCERTAINTIES	139
E. CONCLUSIONS.....	144
F. RECOMMENDATIONS.....	144
VII. 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN (TCDD).....	145
A. EXPOSURE ROUTES AND RECEPTORS.....	146
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	146
1. Distribution	146
2. Metabolism and Excretion	146

C. BIOAVAILABILITY.....	147
1. Inhalation	147
2. Ingestion	147
3. Dermal.....	148
4. Summary	149
D. UNCERTAINTIES	149
E. CONCLUSIONS.....	154
F. RECOMMENDATIONS.....	154
VIII. POLYNUCLEAR AROMATIC HYDROCARBONS (PAHs).....	155
A. EXPOSURE ROUTES AND RECEPTORS.....	156
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	157
1. Distribution.....	157
2. Metabolism and Excretion.....	157
C. BIOAVAILABILITY.....	158
1. Inhalation.....	158
a. Humans.....	158
b. Animals.....	158
2. Ingestion.....	159
a. Humans.....	159
b. Animals.....	159
3. Dermal	159
a. Humans.....	159
b. Animals.....	160
4. Summary.....	162
D. UNCERTAINTIES	162
E. CONCLUSIONS.....	172
F. RECOMMENDATIONS.....	173
IX. BENZENE.....	174
A. EXPOSURE ROUTES AND RECEPTORS.....	174
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	175
1. Distribution.....	175
2. Metabolism	175
3. Excretion	176
C. BIOAVAILABILITY.....	176
1. Inhalation.....	176
a. Humans.....	176
b. Animals.....	176
2. Ingestion.....	177
3. Dermal	177
a. Humans.....	177
b. Animals.....	177
4. Summary.....	178
E. UNCERTAINTIES	178
E. CONCLUSIONS.....	179
F. RECOMMENDATIONS.....	183

X. TOLUENE.....	184
A. EXPOSURE ROUTES AND RECEPTORS.....	184
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	184
1. Distribution.....	184
2. Metabolism and Excretion.....	185
C. BIOAVAILABILITY.....	185
1. Inhalation.....	185
2. Ingestion.....	186
a. Humans.....	186
b. Animals.....	186
3. Dermal.....	186
a. Humans.....	186
b. Animals.....	187
4. Summary.....	187
D. UNCERTAINTIES.....	191
E. CONCLUSIONS.....	191
F. RECOMMENDATIONS.....	192
XI. POLYCHLORINATED PHENOLS:	
PENTACHLOROPHENOL,	
2,4,5-TRICHLOROPHENOL,	
2,4,6-TRICHLOROPHENOL,	
2,3,4,5-TETRACHLOROPHENOL.....	193
A. EXPOSURE ROUTES AND RECEPTORS.....	194
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	194
1. Distribution.....	194
2. Metabolism.....	194
C. BIOAVAILABILITY.....	195
1. Inhalation.....	195
2. Ingestion.....	195
a. Humans.....	195
b. Animals.....	196
3. Dermal.....	196
4. Summary.....	196
D. UNCERTAINTIES.....	197
E. CONCLUSIONS.....	201
F. RECOMMENDATIONS.....	202
XII. PHENOL.....	203
A. EXPOSURE ROUTES AND RECEPTORS.....	203
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	203
1. Distribution.....	203
2. Metabolism.....	203
C. BIOAVAILABILITY.....	204
1. Inhalation.....	204
2. Ingestion.....	204
3. Dermal.....	204

4. Summary.....	205
D. UNCERTAINTIES	205
E. CONCLUSIONS.....	209
F. RECOMMENDATIONS.....	209
XIII. ANILINE.....	210
A. EXPOSURE ROUTES AND RECEPTORS.....	210
B. TOXICOKINETICS (FOLLOWING ABSORPTION).....	210
1. Distribution.....	210
2. Metabolism and Excretion.....	210
C. BIOAVAILABILITY.....	211
1. Inhalation.....	211
2. Ingestion.....	211
3. Dermal	211
4. Summary.....	211
D. UNCERTAINTIES	211
E. CONCLUSIONS.....	213
F. RECOMMENDATIONS.....	213

Chapter 6

BIOAVAILABILITY OF XENOBIOTICS FROM CONTAMINATED SITES	215
I. IDENTIFICATION OF EXPOSURE ROUTES.....	215
II. RELIABILITY AND VALIDITY OF THE BIOAVAILABILITY FACTORS.....	216
A. CHOICE OF EXPERIMENTAL METHODS	216
B. ANALYTICAL CAPABILITIES	222
C. SPECIES DIFFERENCES.....	222
D. MIXTURES AND VEHICLES	222
E. MECHANISM OF TOXICITY	222
F. CHEMICAL FORMS	223
G. EXPOSURE DURATION AND FREQUENCY	223
III. PRIORITY NEEDS FOR FURTHER RESEARCH.....	224

Chapter 7

CONSIDERATIONS FOR APPLYING BIOAVAILABILITY TO HEALTH RISK ASSESSMENT	227
I. METALS.....	227
II. ORGANIC XENOBIOTICS	228
III. OTHER APPLICATION CONSIDERATIONS.....	228
IV. RISK MANAGEMENT CONSIDERATIONS	230
REFERENCES.....	237
GLOSSARY OF TERMS.....	285
INDEX.....	291

LIST OF TABLES

Table 1-1	Parameters Needed for Calculation of External Dose and Internal Dose.....	3
Table 3-1	Main Physiological Functions of the Respiratory Tract	23
Table 3-2	Main Physiological Functions of the Gastrointestinal Tract	39
Table 3-3	The Barriers and Rate-Limiting Processes for Absorption of Xenobiotics through Three Exposure Routes.....	49
Table 3-4	Factors Influencing Bioavailability in Humans	50
Table 4-1	Choice of Experimental Methods for Study of Bioavailability	71
Table 5-1	Respiratory Bioavailability of Arsenic in Humans and Animals.....	84
Table 5-2	Oral Bioavailability of Arsenic in Humans.....	85
Table 5-3	Oral Bioavailability of Arsenic in Animals	86
Table 5-4	Dermal Bioavailability of Arsenic in Animals <i>in vivo</i> and <i>in vitro</i>	88
Table 5-5	Respiratory Bioavailability of Cadmium in Humans and Animals	96
Table 5-6	Oral Bioavailability of Cadmium in Humans	97
Table 5-7	Oral Bioavailability of Cadmium in Animals.....	98
Table 5-8	Dermal Bioavailability of Cadmium in Humans and Animals.....	99
Table 5-9	Respiratory Bioavailability of Chromium in Animals.....	109
Table 5-10	Oral Bioavailability of Chromium in Humans.....	110
Table 5-11	Oral Bioavailability of Chromium in Animals.....	111
Table 5-12	Dermal Bioavailability of Chromium in Animals.....	113
Table 5-13	Experiments of Oral Bioavailability of Copper in Humans	122
Table 5-14	Respiratory Bioavailability of Mercury in Humans and Animals	130
Table 5-15	Oral Bioavailability of Mercury in Humans and Animals.....	131
Table 5-16	Dermal Bioavailability of Mercury in Humans and Animals.....	132
Table 5-17	Respiratory Bioavailability of Lead in Humans.....	140
Table 5-18	Oral Bioavailability of Lead in Humans	141
Table 5-19	Dermal Bioavailability of Lead in Humans and Animals.....	143
Table 5-20	Respiratory Bioavailability of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in Animals	151

Table 5-21a	Relative Oral Bioavailability of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Humans and Animals	151
Table 5-21b	Oral Bioavailability of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Humans and Animals.....	152
Table 5-22	Dermal Bioavailability of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Humans and Animals.....	153
Table 5-23	Respiratory Bioavailability of Some PAHs in Animals.....	164
Table 5-24	Oral Bioavailability of Some PAHs in Animals.....	165
Table 5-25	Dermal Bioavailability of Some PAHs in Humans and Animals (<i>in vivo</i> and <i>in vitro</i>).....	166
Table 5-26	Respiratory Bioavailability of Benzene in Humans.....	180
Table 5-27	Oral Bioavailability of Benzene in Animals	180
Table 5-28	Dermal Bioavailability of Benzene in Humans and Animals (<i>in vivo</i>).....	181
Table 5-29	Dermal Bioavailability of Benzene in Humans and Animals (<i>in vitro</i>).....	182
Table 5-30	Respiratory Bioavailability of Toluene in Humans.....	188
Table 5-31	Oral Bioavailability of Toluene in Humans and Animals.....	189
Table 5-32	Dermal Bioavailability of Toluene in Humans and Animals.....	190
Table 5-33	Respiratory Bioavailability of Pentachlorophenol in Humans and Animals	198
Table 5-34	Oral Bioavailability of PCP and 2,4,6-T ₃ CP in Humans and Animals	199
Table 5-35	Dermal Bioavailability of PCP and 2,4,6-T ₃ CP in Humans and Animals	200
Table 5-36	Bioavailability of Phenol in Humans and Animals (<i>in vivo</i>).....	206
Table 5-37	Dermal Bioavailability of Phenol in Humans and Animals (<i>in vitro</i>).....	208
Table 5-38	Bioavailability of Aniline in Humans and Animals	212
Table 6-1	Potential Exposure Routes to Xenobiotics for the General population	217
Table 6-2	Summary of Bioavailability Factors (%), or Permeability in the Case of Dermal Contact, for Selected Xenobiotics	218
Table 7-1	Available Information on Bioavailability Factors for Selected Xenobiotics	232

LIST OF FIGURES

Figure 2-1	A blood concentration-time curve.....	9
Figure 2-2	Relationship of various doses, their role and application in quantitative risk assessment.....	18
Figure 3-1	Proposed model of a cell membrane.....	20
Figure 3-2	Diagram of lung and bronchial tree.....	20
Figure 3-3	Diagram of bronchiole and alveoli.....	21
Figure 3-4	Structure of air-blood barrier.....	21
Figure 3-5	Gaseous phase absorption of xenobiotics	24
Figure 3-6	Deposition, retention and clearance of aerosols.....	27
Figure 3-7	Major mechanisms of deposition of inhaled aerosols in the respiratory tract.....	28
Figure 3-8	Regional deposition fraction for aerosols inhaled by humans.....	29
Figure 3-9a	Total deposition fraction vs. aerosol size distribution via nasal and oral inhalation in humans.....	31
Figure 3-9b	Deposition fraction for the upper respiratory tract vs. aerosol size distribution via nasal and oral inhalation in humans	31
Figure 3-9c	Deposition fraction for the tracheobronchial vs. aerosol size distribution via oral inhalation in humans.....	32
Figure 3-9d	Deposition fraction for the pulmonary region vs. aerosol size distribution via nasal and oral inhalation in humans	32
Figure 3-10	Diagram of gastrointestinal tract.....	37
Figure 3-11	Diagram of the wall of gastrointestinal tract.....	37
Figure 3-12	Diagram of the intestinal epithelium.....	38
Figure 3-13	Absorptive steps via ingestion.....	40
Figure 3-14	Diagram of the skin.....	44
Figure 3-15	Absorptive steps via dermal route	46
Figure 4-1	Determination of the bioavailability factor based on mass-balance technique	55
Figure 4-2	A procedure for calculation of the respiratory bioavailability factor of aerosols based on deposition-clearance-retention process	57
Figure 4-3	<i>In vitro</i> experimental methods for studying oral bioavailability.....	63
Figure 4-4	Diagram of a typical diffusion cell	69
Figure 5-1	Respiratory bioavailability of inorganic arsenic in human volunteers.....	79
Figure 5-2	Bioavailability factors of inorganic arsenic in humans and animals by three exposure routes.....	83

Figure 5-3	Bioavailability factors of cadmium in humans and animals by three exposure routes.....	95
Figure 5-4	Bioavailability factors of chromium compounds in humans and animals by three exposure routes.....	108
Figure 5-5	Oral bioavailability factors of copper in humans	120
Figure 5-6	Bioavailability factor vs. daily intake of dietary copper.....	121
Figure 5-7	Bioavailability factors of mercury in humans and animals by three exposure routes.....	129
Figure 5-8	Bioavailability factors of lead in humans and animals by three exposure routes.....	139
Figure 5-9	Bioavailability factors of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in humans and animals by three exposure routes	150
Figure 5-10	Bioavailability factors of benzo[a]pyrene in humans and animals by three exposure routes.....	163
Figure 5-11	Dermal bioavailability factors for individual compounds after application of the PAHs-containing mixtures to animal skin	163
Figure 5-12	Bioavailability factors of benzene in humans and animals by three exposure routes.....	179
Figure 5-13	Bioavailability factors of toluene in humans and animals by three exposure routes.....	187
Figure 5-14	Bioavailability factors for pentachlorophenol in humans and animals by three exposure routes.....	197
Figure 5-15	Bioavailability factors of phenol (<i>in vivo</i>) in humans and animals by three exposure routes.....	205
Figure 7-1	Framework for application of bioavailability factors in quantitative risk assessment.....	234